Business Context and Reporting Period
This Form 8-K Current Report from SeaStar Medical Holding Corp covers the date of June 17, 2026. The filing documents the results of the Company's annual meeting of stockholders, which was held virtually to address director elections, equity plan amendments, and auditor ratification.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and equity plan matters rather than financial performance data.
Material Changes and Corporate Actions
- Equity Plan Amendment: Stockholders approved an amendment to the 2022 Omnibus Incentive Plan, increasing the authorized share pool from 207,046 to 896,546 shares. This adjustment accounts for a 1-for-10 reverse stock split executed on January 5, 2026.
- Director Election: John Neuman was elected as a Class I director to serve until the 2029 annual meeting.
- Auditor Ratification: The appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.
Voting Results and Management Commentary
The following proposals were approved by stockholders:
- Proposal 1 (Director Election): 757,141 votes For; 23,212 votes Against; 4,829 Abstentions. Notably, there were 1,395,732 Broker Non-Votes.
- Proposal 2 (Equity Plan Increase): 551,233 votes For; 223,813 votes Against; 10,136 Abstentions. There were 1,395,732 Broker Non-Votes.
- Proposal 3 (Auditor Ratification): 2,151,096 votes For; 22,746 votes Against; 7,072 Abstentions.
- Proposal 4 (Adjournment Authority): 2,035,262 votes For; 123,747 votes Against; 21,905 Abstentions.
The filing includes no specific management commentary regarding future outlook, risks, or contingencies beyond the standard incorporation of the Proxy Statement and the Incentive Plan by reference.
Investor Verification Checklist
- Verify the impact of the increased equity pool (896,546 shares) on potential future dilution.
- Review the definitive Proxy Statement filed on April 29, 2026, for the full terms of the 2022 Omnibus Incentive Plan.
- Confirm the details of the 1-for-10 reverse stock split executed on January 5, 2026, and its effect on share counts.
- Assess the significance of the high number of Broker Non-Votes (1,395,732) relative to the total votes cast on Proposals 1 and 2.